ライフサイエンスコーパス: pfu

1 PFU, 3 received 100 PFU, and 3 received 1000 PFU).

2 during pregnancy with wild-type GPCMV (10(5) PFU).

3 eroconverted (the seroconverter received 100 PFU).

4 xposed to aerosolized monkeypox virus (10(5) PFU).

5 nuates mouse neuroinvasiveness (>/=1,000,000 PFU).

6 : wild-type mice, 10 PFU; CD1(-/-) mice, 1.6 PFU).

7 ted (1 received 100 PFU, and 2 received 1000 PFU).

8 ose vaccinated with 3 million or 100 million PFU.

9 ce of UL88, as more genomes are required per PFU.

10 ge at a median protective dose (PD50) of 2.4 PFU.

11 4 x 10(5) PFU; (NA+HA)(Min), >/=3.16 x 10(6) PFU.

12 of 800-2200 PFU and a detection limit of 600 PFU.

13 ven after intracerebral inoculation of 10(3) PFU.

14 e PKR(-/-) mice succumbed at a dose of 10(8) PFU.

15 ring in animals infected with 10(6) or 10(7) pfu.

16 intraperitoneal route, with an LD(50) of 14 PFU.

17 est African clade yielded an LD(50) of 7,600 PFU.

18 ted elevated ratios of virion DNA copies per PFU.

19 which reached, respectively, 0.005 and 0.017 PFU.

20 than 50% of participants at doses >/=3 x 105 PFU.

21 AST mice, whereas BALB/c mice survived 10(6) PFU.

22 persisted up to day 180 for doses >/=3 x 105 PFU.

23 able dose of 50 PFU and a lethal dose of 500 PFU.

24 ainst RSV challenge at doses as low as 10(3) PFU.

25 doses of EBOV (</=100 plaque-forming units [PFU]).

26 ting Bacteroides GB-124 (mean = 4.36 log(10) PFU/100 mL) and that GB-124 phages, HAdV, and NoV were a

27 centrations of 1.71 x 10(2) and 4.27 x 10(2) PFU/100 mL, respectively, higher than nonhost specific R

28 tly reduced specific infectivity (si) (WT, 1 PFU/118 particles vs. P2(Min), 1 PFU/35,000 particles),

29 BOV vaccine (3 million plaque-forming units [PFU], 20 million PFU, or 100 million PFU) or placebo.

30 Vax-WN02 3.7- x -10(5) plaque-forming units (PFU), 3.7 x 10(4) PFU, 3.7 x 10(3) PFU, or placebo.

31 a 4, 7 subjects seroconverted (1 received 10 PFU, 3 received 100 PFU, and 3 received 1000 PFU).

32 0(5) plaque-forming units (PFU), 3.7 x 10(4) PFU, 3.7 x 10(3) PFU, or placebo.

33 (si) (WT, 1 PFU/118 particles vs. P2(Min), 1 PFU/35,000 particles), a phenotype that will be discusse

34 paratuberculosis cells ranging from 1 to 110 PFU/50 ml of milk and 6 to 41,111 PFU/g of feces were in

35 vaccinees (22%) receiving 10(7) or 5 x 10(7) pfu, 56 participants were given a lower dose (3 x 10(5)

36 oses ranging from 1.0 x 10(3) to 1.0 x 10(5) PFU administered subcutaneously (s.c.).

37 e upper and lower airways by 3.8 log10 total PFU and 2.7 log10 PFU/g of tissue, respectively, compare

38 d to quantitate VSV in the range of 800-2200 PFU and a detection limit of 600 PFU.

39 cted with 2 inocula: a survivable dose of 50 PFU and a lethal dose of 500 PFU.

40 re frequent at high vaccine doses (9 x 10(6) PFU and greater).

41 illion and 100 million plaque-forming units (PFU) and homologous VSV-Ebola vaccine boost in healthy a

42 nd wild-type cPKCalpha (Ad WTPKCalpha, 10(7) pfu), and proliferation was measured.

43 negative nPKCepsilon (Ad DNPKCepsilon, 10(4) pfu), and wild-type cPKCalpha (Ad WTPKCalpha, 10(7) pfu)

44 2, 3 subjects seroconverted (1 received 100 PFU, and 2 received 1000 PFU).

45 converted (1 received 10 PFU, 3 received 100 PFU, and 3 received 1000 PFU).

46 llion or 100 million PFU than with 3 million PFU, and these correlated strongly with neutralization t

47 ase (Ad-Cre; 2 x 10(7) plaque forming units [PFU]) and adeno-associated viral vectors expressing VEGF

48 irus serotype 2 (strain 16 681) at 1 x 10(7) PFU/animal.

49 crRNAs from the 7 shared CRISPR loci in Pfu are processed for use by all 3 effector complexes, a

50 Type III-B immunity in Pyrococcus furiosus (Pfu) are regulated by target RNA features and second mes

51 FU than in the group that received 3 million PFU, as assessed by ELISA and by pseudovirion neutraliza

52 Surprisingly, animals exposed to 10 PFU by either route showed no signs of disease.

53 edian mosquito-inoculated dose of WNV (10(5) PFU) by needle.

54 (50% lethal dose titers: wild-type mice, 10 PFU; CD1(-/-) mice, 1.6 PFU).

55 ched, with loss of most infectious virus (<5 PFU/cell) by 20 to 24 h p.i.

56 .i.]) after maximal virus titers (150 to 200 PFU/cell) have been reached, with loss of most infectiou

57 ing infection at low multiplicity (MOI = 0.1 PFU/cell) inhibited HCMV in a dose-dependent manner and

58 a low multiplicity of infection (MOI; 0.0001 PFU/cell) or with 2009 pandemic H1N1 viruses at a high M

59 2009 pandemic H1N1 viruses at a high MOI (10 PFU/cell).

60 (viability: control, 33.02+/-1.09%; LacZ 10 pfu/cell, 32.85+/-1.51%; catalase 1 pfu/cell, 62.09+/-4.

61 LacZ 10 pfu/cell, 32.85+/-1.51%; catalase 1 pfu/cell, 62.09+/-4.17%*; catalase 2 pfu/cell, 98.71+/-3

62 alase 1 pfu/cell, 62.09+/-4.17%*; catalase 2 pfu/cell, 98.71+/-3.35%*; catalase 10 pfu/cell, 99.68+/-

63 lase 2 pfu/cell, 98.71+/-3.35%*; catalase 10 pfu/cell, 99.68+/-1.99%*; *p<0.05 vs. control; mean+/-SE

64 ed at a multiplicity of infection (MOI) of 3 PFU/cell.

65 cine prevented deaths from a low dose (10(3) PFU) challenge, though they experienced viremia and body

66 cient to ensure <8 Phi6 plaque-forming unit (PFU)/cm(2) in all tests.

67 The Pfu Cmr complex cleaves complementary target RNAs, and C

68 challenging the animals with 10(5) or 10(6) PFU Congo Basin MPXV 30 days postvaccination and evaluat

69 s, we evaluated cellular responses and viral PFU counts in murine RAW264.7 cells and primary macropha

70 of the adenosine-specific endoribonuclease, Pfu Csx1, degrades cOA signaling molecules to provide an

71 s that activate the ribonuclease activity of Pfu Csx1.

72 Virus was eluted from the swabs and PFU determined by titration on human A549 cells, accordi

73 we evolved a version of Pyrococcus furiosus (Pfu) DNA polymerase that tolerates modification of the g

74 ology 3 domain binds directly to the central PFU domain of Doa1.

75 ant-negative cPKCalpha (Ad DNPKCalpha, 10(4) pfu), dominant-negative nPKCepsilon (Ad DNPKCepsilon, 10

76 At the 2 x 10(7) PFU dose (used in phase 3 trials), the most common local

77 ty and immunogenicity profile of the 2 x 107 PFU dose in adults and support consideration of lower do

78 In RSV-seronegative children, the 105 PFU dose was overattenuated, but the 106 PFU dose was we

79 105 PFU dose was overattenuated, but the 106 PFU dose was well tolerated, infectious (RSV/DeltaNS2/De

80 On day 28 at the 2 x 10(7) PFU dose, the geometric mean IgG ELISA endpoint titre wa

81 y results support selection of the 2 x 10(7) PFU dose.

82 x 10(3), 3 x 10(4), 3 x 10(5), or 3 x 10(6) PFU doses of rVSVG-ZEBOV-GP or placebo.

83 x 10(6), 9 x 10(6), 2 x 10(7), or 1 x 10(8) PFU doses of rVSVG-ZEBOV-GP or placebo.

84 At 3 x 10(5) pfu, early-onset reactogenicity remained frequent (45 [8

85 form of PKCalpha (Ad-myr-PKCalpha, 1 x 10(7) pfu), EGF (10(-7) M), or both.

86 affected the severity of disease, with 10(4) pfu eliciting milder keratitis after delayed onset compa

87 on, and it is associated with an increase of PFU, especially under serum-free conditions in the later

88 , mice were ocularly infected with 2 x 10(4) PFU/eye of virulent HSV-1 strain McKrae.

89 A viral inoculum of 10(5) pfu/eye was determined to be optimal for use in further

90 ritoneal dose of vaccinia virus (VACV) was 3 PFU for CAST mice, whereas BALB/c mice survived 10(6) PF

91 The detection threshold was 0.017 PFU for DENV-1, 0.004 PFU for DENV-2, 0.8 PFU for DENV-3

92 on threshold was 0.017 PFU for DENV-1, 0.004 PFU for DENV-2, 0.8 PFU for DENV-3, and 0.7 PFU for DENV

93 17 PFU for DENV-1, 0.004 PFU for DENV-2, 0.8 PFU for DENV-3, and 0.7 PFU for DENV-4.

94 PFU for DENV-2, 0.8 PFU for DENV-3, and 0.7 PFU for DENV-4.

95 evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a secon

96 y sensitive, detecting H5 virus levels of <1 PFU from each of the HA clades.

97 m 1 to 110 PFU/50 ml of milk and 6 to 41,111 PFU/g of feces were indicated by the PMS-phage assay.

98 airways by 3.8 log10 total PFU and 2.7 log10 PFU/g of tissue, respectively, compared to those in unva

99 With an intermediate dose of 2 x 10(3) PFU, genomic diversity present in nasal lavage samples i

100 r LD50 values: PR8, 32 plaque-forming units (PFU); HA(Min), 1.7 x 10(3) PFU; NA(Min), 2.4 x 10(5) PFU

101 Pyrococcus furiosus (Pfu) harbors three CRISPR-Cas immune systems: a Cst (Typ

102 ltaG-ZEBOV-GP (2 x 107 plaque-forming units [pfu]), high-dose 1 x 108 pfu, or placebo.

103 With a high dose of 2 x 10(6) PFU, however, reassortment levels were high (avg. 59%) a

104 x 103, 3 x 104, 3 x 105, 3 x 106, or 2 x 107 PFU in 115 adults and a dose of 2 x 107 PFU in 20 adoles

105 107 PFU in 115 adults and a dose of 2 x 107 PFU in 20 adolescents and 20 children.

106 RSV-seropositive children and at 105 and 106 PFU in 21 and 30 RSV-seronegative children, respectively

107 ebo ratio, 2:1) at 106 plaque-forming units (PFU) in 15 RSV-seropositive children and at 105 and 106

108 e when used at 2 x 107 plaque-forming units (PFU) in a trial in Guinea.

109 se of 10, 100, or 1000 plaque-forming units (PFU) in cohorts of 3.

110 with sensitivity of 5 plaque-forming units (PFU) in less than 40 min.

111 ved with high challenge dosages (1.0 x 10(4) PFU) in the rat lethal disease model.

112 atio of genome-containing viral particles to PFU indicated that Slfn11 impairs WNV infectivity.

113 strain) was measured by plaque-forming unit (PFU) inhibition.

114 -dose (2 x 10(8) PFU) or low-dose (1 x 10(7) PFU) intramuscular immunization of rhesus macaques.

115 d to vaccination with a high dose (2,000,000 PFU), intranasal inoculation with a low dose (200 PFU) r

116 of gestation with virulent RVFV (1.0 x 10(6) PFU intravenously).

117 ations of MS2 and Phi6 were approximately 20 PFU L(-1) and approximately 0.1 PFU L(-1), respectively,

118 oximately 20 PFU L(-1) and approximately 0.1 PFU L(-1), respectively, in the chambers enclosing the a

119 nt the binding sites of Pyrococcus furiosus (Pfu) L7Ae on its cognate RNase P RNA (RPR).

120 wabs with different concentrations of ZIKAV (PFU/microL).

121 med by the limit of detection (as low as 0.1 PFU/microL, equivalent to copy number of 4.9) in spiked

122 respectively, for the aeration basin and 79 PFU min(-1) and 0.3 PFU min(-1) for the sewer pipes.

123 ding emission rates of MS2 and Phi6 were 547 PFU min(-1) and 3.8 PFU min(-1), respectively, for the a

124 he aeration basin and 79 PFU min(-1) and 0.3 PFU min(-1) for the sewer pipes.

125 of MS2 and Phi6 were 547 PFU min(-1) and 3.8 PFU min(-1), respectively, for the aeration basin and 79

126 U mL(-)(1)), giving detection limit of 0.230 PFU mL(-)(1) and 0.710 PFU mL(-)(1) respectively.

127 ection limit of 0.230 PFU mL(-)(1) and 0.710 PFU mL(-)(1) respectively.

128 and dengue 3 viruses in plaque forming unit (PFU mL(-)(1)), giving detection limit of 0.230 PFU mL(-)

129 ly 30 ng ml(-1), 4 x 10(4) cfu ml(-1), 10(6) pfu ml(-1) and 2 x 10(7) cfu ml(-1).

130 reporter phage concentration of 1.76 x 10(2) pfu ml(-1) are capable of detecting approximately 5 CFU

131 s achieved within 9 hours using 9.23 x 10(3) pfu ml(-1) of phage in selective culture enrichments of

132 n a linear range from 5 x 10(4) to 5 x 10(6) PFU mL(-1) with a detection limit of 10(4) PFU mL(-1).

133 of 3-45 plaque-forming units per milliliter (pfu mL(-1)) with detection limit of 0.04 pfu mL(-1), com

134 f 10(7) plaque-forming units per milliliter (PFU mL(-1)), were not detected in air after flushing.

135 er (pfu mL(-1)) with detection limit of 0.04 pfu mL(-1), comparable to state-of-the-art polymerase ch

136 ) PFU mL(-1) with a detection limit of 10(4) PFU mL(-1).

137 EBOV and SUDV were 465 plaque-forming units (PFU)/mL (1010 copies/mL) and 324 PFU/mL (8204 copies/mL)

138 etection of less than 1 plaque forming unit (pfu)/mL in a direct EIS assay.

139 , producing 2.9 x 10(6) plaque-forming unit (PFU)/mL of virus.

140 lectric signal up to 10 Plaque forming unit (PFU)/mL with a limit of detection (LOD) of 8.75 PFU/mL.

141 mit of detection reached the order of 10(3) (PFU)/mL, only 10-times less sensitive than RT-PCR and mo

142 ming units (PFU)/mL (1010 copies/mL) and 324 PFU/mL (8204 copies/mL), respectively.

143 D) of the dual-channel PSPWB for S-OIV is 30 PFU/mL (PFU, plaque-forming unit), which was calculated

144 ects and allowed low limits of detection (12 pfu/mL and 39 pfu/mL in buffer and in river water, respe

145 lent sensitivity and limit of detection (9.3 pfu/mL and 9.8 pfu/mL in buffer and in river water, resp

146 ent specificity, a limit of detection of 0.2 pfu/mL and a dynamic range of thirteen orders of magnitu

147 15 min with reasonable sensitivity of 10(7) pfu/mL and minimal sample preparation, making this trans

148 ne (median peak nasal wash titers: 3.1 log10 PFU/mL by immunoplaque assay; 5.1 log10 copies/mL by rev

149 ed low limits of detection (12 pfu/mL and 39 pfu/mL in buffer and in river water, respectively) that

150 y and limit of detection (9.3 pfu/mL and 9.8 pfu/mL in buffer and in river water, respectively) were

151 mmunosensor showed a limit of detection of 6 pfu/mL in buffer, allowing the detection of MS2 to level

152 ured S-OIV at a concentration of 1.8 x 10(2) PFU/mL in mimic solution, which contained PBS-diluted no

153 OD for S-OIV in PBS was determined to be 3.5 PFU/mL in this experiment.

154 ntrations, followed by incubation with 10(3) PFU/ml of D29 mycobacteriophage for 24 h and then real-t

155 ed peak viremia titers of 2.8 to 3.1 log(10) PFU/ml on day 2 or 4 after infection, but there was no d

156 detection range was determined to be from 10 PFU/mL to 5000 PFU/mL with an R(2) value greater than 0.

157 was determined to be from 10 PFU/mL to 5000 PFU/mL with an R(2) value greater than 0.9.

158 e recombinant RVs grew to high titer (>10(7) PFU/ml) and remained genetically stable during serial pa

159 cate rapidly and to high titer (up to 10(10) PFU/ml) in mosquito cells, producing extensive cytopathi

160 High (>10(7) PFU/ml) viral loads were detected in all major organs (l

161 ained high virulence (MLD50, up to 0.5 log10 PFU/mL) within 5 passages.

162 razide and hydroxyl diothiolated linkers (15 pfu/mL).

163 imit of detection of the Xpert test was 0.01 PFU/ml.

164 phage particles ranging from 10(2) to 10(6) pfu/mL.

165 saline (PBS) over a range of 18-1.8 x 10(6) PFU/mL.

166 recombinant virus reaches titers of >/=10(4) pfu/mL.

167 n ability for DENV detection as low as 10(4) PFU/mL.

168 )/mL with a limit of detection (LOD) of 8.75 PFU/mL.

169 0(7) plaque-forming unit (PFU) mm(-2) (~2550 PFU mm(-2) s(-1)) with a retention efficiency depending

170 ges of up to ~4 x 10(7) plaque-forming unit (PFU) mm(-2) (~2550 PFU mm(-2) s(-1)) with a retention ef

171 fer were inoculated intranasally with 10,000 PFU/mouse influenza A/WSN/33 (H1N1) virus.

172 tely expressed and purified fragments, split Pfu mutant behaves identically to wild-type DNA polymera

173 ad received 1 x10(7) pfu (n=35) or 5 x 10(7) pfu (n=16) of rVSV-ZEBOV (high-dose vaccinees) or placeb

174 with 59 volunteers who had received 1 x10(7) pfu (n=35) or 5 x 10(7) pfu (n=16) of rVSV-ZEBOV (high-d

175 igh-dose lot of rVSVDeltaG-ZEBOV-GP (1 x 108 pfu, n = 264; high-dose group), or placebo (n = 133).

176 ticipants were given a lower dose (3 x 10(5) pfu, n=51) or placebo (n=5) to assess the effect of dose

177 taG- ZEBOV-GP (2 x 107 plaque-forming units [pfu], n = 797; combined-lots group), a single high-dose

178 ue-forming units (PFU); HA(Min), 1.7 x 10(3) PFU; NA(Min), 2.4 x 10(5) PFU; (NA+HA)(Min), >/=3.16 x 1

179 (Min), 1.7 x 10(3) PFU; NA(Min), 2.4 x 10(5) PFU; (NA+HA)(Min), >/=3.16 x 10(6) PFU.

180 n the absence of hormone pretreatment, 2,000 PFU of a clinical isolate of HSV-2 was sufficient to est

181 at pigs treated with 10(8), 10(9), or 10(10) PFU of Ad5-poIRF7/3(5D) 24 h before FMDV challenge were

182 re detectable in 1 subject (who received 100 PFU of chimera 4).

183 was evaluated following inoculation of 10(7) PFU of Delta145 or parental virus into guinea pigs immun

184 guinea pigs twice with either 10(5) or 10(6) PFU of Delta145, establishing pregnancy, and challenging

185 laque-forming units (PFU) of DENV-1 or 10(5) PFU of DENV-3.

186 tly challenged 19 weeks later with 1 x 10(5) PFU of DENV2.

187 e protected against challenge with 2 x 10(7) PFU of homologous HPAIV.

188 mice were injected in one AC with 3 x 10(4) PFU of HSV-1 (KOS) in a volume of 2 microL.

189 n infected immediately thereafter with 10(4) PFU of HSV-1 strain 17syn+.

190 Following corneal infection with 2 x 10(6) PFU of HSV-1 strain McKrae, 50% of wild-type mice surviv

191 333, and/or G) at a total dose of 1 x 10(7) PFU of HSV-2 per animal.

192 10(5) T cells prior to challenge with 10(4) PFU of IHD-J-Luc and treated with BCV postchallenge surv

193 organs, and survived rechallenge with 10(5) PFU of IHD-J-Luc VACV without additional BCV treatment.

194 LB/c mice using coinfection with 1 x 10(4.5) PFU of influenza A virus MEM H3N2, followed by intranasa

195 eral vaccination of mice with 10(1) or 10(3) PFU of JCV/LACV protected against lethal challenge with

196 (NAb) from TDV were revaccinated with 10(4) PFU of live attenuated DENV-3 vaccine to evaluate memory

197 were inoculated intraperitoneally with 10(7) PFU of parental or recombinant SV40 viruses and were obs

198 infected via the intranasal route with 10(5) PFU of recombinant IHD-J-Luc VACV expressing luciferase.

199 C3H/HeN mice infected with 3 x 10(5) PFU of Rickettsia conorii developed an acute progressive

200 accinated orally with a single dose of 10(8) PFU of rPIV5-RV-G showed a 50% survival rate, which is c

201 mice vaccinated with a single dose of 10(8) PFU of rPIV5-RV-G via the i.m. route showed very robust

202 A single dose of 10(6) PFU of rPIV5-RV-G was sufficient for 100% protection whe

203 STAT2 are highly susceptible to as few as 10 PFU of SFTSV, with animals generally succumbing within 5

204 ue-forming units [PFU] of TDV-1; 6.3 x 10(3) PFU of TDV-2; 3.2 x 10(4) PFU of TDV-3; and 4.0 x 10(5)

205 TDV-1; 6.3 x 10(3) PFU of TDV-2; 3.2 x 10(4) PFU of TDV-3; and 4.0 x 10(5) PFU of TDV-4) in different

206 2; 3.2 x 10(4) PFU of TDV-3; and 4.0 x 10(5) PFU of TDV-4) in different dose schedules (two-dose regi

207 s were trephined and inoculated with 1x10(5) pfu of the Dryvax strain of the vaccinia virus.

208 hal disease when challenged with as few as 4 PFU of the Romero strain of JUNV.

209 d lower respiratory tract at a dose of 10(6) PFU of vaccine.

210 hat infection of C57BL/6 mice with 1 x 10(7) PFU of vaccinia virus strain WR results in blepharitis,

211 time of intranasal challenge with 2 x 10(6) PFU of vaccinia virus, resulted in complete protection a

212 ainst viremia when challenged with 1 x 10(5) pfu of virulent RVF virus delivered by a small particle

213 e L(-/-) PKR(-/-) mice inoculated with 10(8) PFU of VVDeltaE3L, with a distinct pathology.

214 he anti-ZIKV-PSBs can capture as little as 1 PFU of ZIKV in 100 mul of saline, human plasma, or human

215 laterally with 2x10(6) plaque-forming-units (PFU) of adenovirus type 5 (Ad5) after corneal scarificat

216 lation of either 10(3) plaque-forming units (PFU) of DENV-1 or 10(5) PFU of DENV-3.

217 intranasal dose of 105 plaque-forming units (PFU) of LID/DeltaM2-2/1030s (n = 21) or placebo (n = 11)

218 s receiving no or the lowest dose (1 x 10(5) PFU) of MVA/GM-CSF resisted all 12 challenges.

219 5 x 10(4) or 1 x 10(5) plaque-forming units (pfu) of Rift Valley fever (RVF) MP-12 vaccine by oral, i

220 10(5), 10(6), or 10(7) plaque-forming units (pfu) of the Dryvax strain of the vaccinia virus and scor

221 rs receiving 3 x 10(5) plaque-forming units (pfu) of the recombinant vesicular stomatitis virus-based

222 containing 2.5 x 10(4) plaque-forming units [PFU] of TDV-1; 6.3 x 10(3) PFU of TDV-2; 3.2 x 10(4) PFU

223 ral titers peaked at approximately 1 x 10(6) PFU on day 5 postinfection, and virus had not cleared by

224 At a dose of 2 x 10(2) PFU, one parental virus was absent from each guinea pig

225 icipants received single-injection 3 x 10(5) pfu open-label.

226 3 deployable participants received 3 x 10(5) pfu open-label.

227 igher in the groups that received 20 million PFU or 100 million PFU than in the group that received 3

228 e 130 participants (95%) receiving 3 million PFU or more; rVSV was not detected in saliva or urine.

229 ing sizes to a single injection of 3 x 10(5) pfu or placebo, whereas deployable participants received

230 mized to receive ChimeriVax-WN02 3.7 x 10(5) PFU or placebo.

231 esult in a fatal infection at doses below 10 PFU or with exposure times as short as 2 min.

232 gimens utilizing either high-dose (2 x 10(8) PFU) or low-dose (1 x 10(7) PFU) intramuscular immunizat

233 ants received low-dose rVSV-ZEBOV (3 x 10(5) pfu) or placebo in a double-blind fashion, whereas 13 de

234 units [PFU], 20 million PFU, or 100 million PFU) or placebo.

235 300,000 to 50 million plaque-forming units (PFU) or placebo.

236 llion plaque-forming units [PFU], 20 million PFU, or 100 million PFU) or placebo.

237 aque-forming units [pfu]), high-dose 1 x 108 pfu, or placebo.

238 ng units (PFU), 3.7 x 10(4) PFU, 3.7 x 10(3) PFU, or placebo.

239 33%) pups in the group vaccinated with 10(6) PFU (P < 0.05).

240 h-dose vaccinees receiving at least 1 x10(7) pfu (p<0.0001).

241 bserved across pancreatic cell lines with 10 PFU per cell combined with 1 and 2 mM 5-ALA.

242 o pancreatic lines (mean 57% [SE 10.2] at 10 PFU per cell).

243 but poorly in PML(-/-) cells exposed to 0.1 pfu per cell.

244 The specific infectivities (PFU per viral genome) of HSV(chol) and HSV(des) were sim

245 ) at 0, 0.1, 1, and 10 plaque-forming units (PFU) per cell for 48 h.

246 atalase, with up to 10 plaque forming units (pfu) per neuron, did not affect cell viability under con

247 e dual-channel PSPWB for S-OIV is 30 PFU/mL (PFU, plaque-forming unit), which was calculated from the

248 y B DNA polymerase from Pyrococcus furiosus (Pfu Pol) contains sensitive determinants of both dNTP bi

249 ics of the enzyme as well as the fidelity of Pfu Pol.

250 PCR amplification using a high-fidelity DNA Pfu polymerase generating a plasmid containing staggered

251 f primer-templates with Pyrococcus furiosus (Pfu) polymerase-DNA complexes containing uracil at +2; m

252 to receive 2 x NYVAC-B followed by 1 x 1010 PFU rAd5 (NYVAC/Ad5hi); 1 x 108 PFU rAd5 followed by 2 x

253 owed by 2 x NYVAC-B (Ad5med/NYVAC); 1 x 1010 PFU rAd5 followed by 2 x NYVAC-B (Ad5hi/NYVAC); or place

254 by 1 x 1010 PFU rAd5 (NYVAC/Ad5hi); 1 x 108 PFU rAd5 followed by 2 x NYVAC-B (Ad5lo/NYVAC); 1 x 109

255 llowed by 2 x NYVAC-B (Ad5lo/NYVAC); 1 x 109 PFU rAd5 followed by 2 x NYVAC-B (Ad5med/NYVAC); 1 x 101

256 5 cells, and the viral genome copy number-to-PFU ratio for VZV in human neurons was 500, compared wit

257 ampered by the fact that the VZV particle-to-PFU ratio has never been determined with precision.

258 4,000- to 20,000-fold increased) particle-to-PFU ratio in vitro than herpes simplex virus (HSV).

259 es, on average, exhibit a higher particle-to-PFU ratio than mosquito cell-derived SINV particles.

260 ay not necessarily have a higher particle-to-PFU ratio than other herpesviruses; instead, the cells p

261 Based on these numbers, the VZV particle:PFU ratio was approximately 40,000:1 for a cell-free ino

262 Particle-to-PFU ratios for E1-139 and E2-196 mutant strains were sim

263 Cell-type-specific particle-to-PFU ratios of HCMV strains that contained different amou

264 ll lines (SINV(C6/36)) exhibited particle-to-PFU ratios similar to those observed for SINV(Heavy).

265 Analyses of particle-to-PFU ratios, relative plaque size, and kinetics of virus

266 ly, producing virions with elevated particle:PFU ratios.

267 us replication levels and decreased particle/PFU ratios.IMPORTANCE Gene inactivation is considered to

268 d increased physical to infectious particle (PFU) ratios, with additional data suggesting that a late

269 ibitory concentration (FIC indices) based on PFU reduction.

270 cells in vitro due to significantly reduced PFU released per infected cell.

271 aline, 1 x 10(6) (BOOP), or 1 x 10(7) (ARDS) PFU reovirus 1/L, and evaluated at various days postinoc

272 10(2) and 10(2)-10(8) plaque forming units (pfu), respectively.

273 e (LD(5)(0)) values of 0.1 and 0.5 log(1)(0) PFU, respectively, chimeric JCV/LACV is highly attenuate

274 Exposure to 100 PFU resulted in illness and/or lethal infection.

275 nge with doses of r129 virus of >/=5 x 10(6) PFU resulted in levels of maternal viremia, congenital t

276 intranasal inoculation with a low dose (200 PFU) resulted in a 10-fold decrease in vector growth in

277 ep-wise, Mg(2+)-dependent reconstitutions of Pfu RNase P with its catalytic RNA subunit and two inter

278 We investigated Pyrococcus furiosus (Pfu) RNase P, an archaeal RNP that catalyzes tRNA 5' mat

279 Pfu RPP21 in solution consists of an unstructured N-term

280 inal deletion mutant of Pyrococcus furiosus (Pfu) RPP29 that is defective in assembling with its bina

281 xperiments with an enzyme assembled with the Pfu RPR and five protein cofactors (POP5, RPP21, RPP29,

282 nctional when reconstituted with the cognate Pfu RPR.

283 At the inoculation dose of 5.0 x 10(6) PFU, rVSV-HSP70-VP1 stimulated significantly higher T ce

284 At the inoculation dose of 1.0 x 10(6) PFU, rVSV-HSP70-VP1 triggered significantly higher vagin

285 ant animals were vaccinated with 1.0 x 10(4) PFU s.c. at day 42 of gestation, when fetal sensitivity

286 function of the Cst as well as Csa system in Pfu strains harboring a single CRISPR-Cas system.

287 assay was 2.8 x 10(2) plaque-forming units (PFU)/test and 1 x 10(3) PFU/test within 40 minutes for E

288 laque-forming units (PFU)/test and 1 x 10(3) PFU/test within 40 minutes for EBOV-Kikwit and EBOV-Mako

289 that received 20 million PFU or 100 million PFU than in the group that received 3 million PFU, as as

290 es in individuals vaccinated with 20 million PFU than in those vaccinated with 3 million or 100 milli

291 e vaccination with 20 million or 100 million PFU than with 3 million PFU, and these correlated strong

292 At inocula above 10(5) pfu the course and severity of corneal disease was not s

293 Infection (with approximately 10(6) PFU, the equivalent of a mosquito bite) of these humaniz

294 ology, and decreased viral titers from 10(6) pfu to undetectable levels.

295 rthermophilic archaeon Pyrococcus furiosus ( Pfu) using conventional and paramagnetic NMR techniques.

296 HPAI H5N1 challenge: a dose as low as 1,000 PFU was sufficient to protect against lethal HPAI H5N1 c

297 e retinas were infected with MCMV (5 x 10(5) PFU/well).

298 a calculated 50% lethal dose (LD(50)) of 680 PFU, whereas there were no deaths of BALB/c mice at a 10

299 ental HEp-2 and PML(-/-) cells infected at 5 pfu wild-type virus per cell, but poorly in PML(-/-) cel

300 protection against a lethal high dose (10(5) PFU) ZIKV challenge, but mtdVSV-NS1-based vaccine preven